|Day Low/High||40.08 / 40.32|
|52 Wk Low/High||36.41 / 42.36|
Gilead Sciences' bictegravir suppressed HIV better than rival Glaxo's dolutegravir.
With stocks at record highs, there are still buying opportunities, but investors should be selective.
Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.
Firms' 13F filings show how they've followed in the footsteps of the father of value investing.
As we all know, the stock market and the economy abhor uncertainty.
Stocks in the health care sector seem to have no underpinnings whatsoever.
For the week of October 24, investors await quarterly results from a slew of major companies, including Apple, along with the first estimate of third quarter GDP.
Which stocks will be most favored by the corporate-bond purchases?
This market is like a leaky helium balloon; watch out for sudden downdrafts.
The pharmaceutical giant is teaming up with Google's parent with as much as $715 million in joint investments.
GlaxoSmithKline and Google's parent Alphabet announced their joint plan to pioneer a new form of electronic medical treatment.
The U.K. isn't going anywhere Brexit vote notwithstanding, and here's a way to get on the most business-friendly state across the pond.
If you think the best thing to do post-Brexit is buy more, here are 4 to consider.
GSK has been largely stuck between $44 on the upside and $37 on the downside for the past 12 months.
The expected legal deluge will be manageable thanks to JNJ's massive size and financial strength.
Jim Cramer says it you are going to own a drug stock, invest in Allergan or Johnson & Johnson.
Jim Cramer says UnitedHealth's stock is going much higher, and it is a 'terrific' name to own.
Shares of GlaxoSmithKline are up a pleasant 5% in 2016 and it currently sports a healthy 6.5% dividend yield.
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
Pfizer scored the top spot in Interbrand Health's inaugural ranking of the top ten biopharmaceutical brands.
With the short-term trend neutral and the longer-term trend down be on guard for a break lower to around $35.
Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
If you have an appetite for risk, there are buying opportunities.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
Stocks were sharply lower at midday in a volatile session to end the week.